Drug Profile
GC 3114
Alternative Names: GC-3114A; GC3114; High-dose quadrivalent influenza vaccine - GC PharmaLatest Information Update: 25 Aug 2021
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 24 Aug 2021 Phase-II development is still ongoing for Influenza virus infections (GC Pharma pipeline, August 2021)
- 17 Mar 2021 Discontinued - Phase-II for Influenza virus infections (In the elderly, Prevention) in South Korea (IM)
- 13 Dec 2018 Green Cross completes a phase II trial in Influenza virus vaccine (Prevention, In elderly) in South Korea (NCT03657719)